Medical technology company ENDRA includes HYPE token in newly established crypto asset portfolio
Jinse Finance reported that medical technology company ENDRA has completed a round of private placement financing to support its entry into the digital asset sector, and has immediately allocated part of the funds to purchase HYPE tokens—which will become a core component of its actively managed asset treasury. According to news on October 23, the Ann Arbor-based medical technology company completed a private investment in public equity (PIPE) round, raising $4.9 million, with institutional and crypto sector investors as the main participants. Meanwhile, the company revealed that it has allocated approximately $3 million from the raised funds to acquire 78,863 Hyperliquid platform tokens (i.e., HYPE tokens). ENDRA Life Sciences stated that this acquisition marks the first implementation of its newly established Digital Asset Treasury (DAT) strategy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
USD/JPY Price Forecast: Hits one week low as bears eye trading range support near 157.50
Susquehanna raises pre-earnings price targets for chip stocks: AMD (AMD.US), Qualcomm (QCOM.US), etc. receive upward revisions
Susquehanna has adjusted the target prices for chip stocks such as AMD, Intel, and Qualcomm.

Wedbush: Hard drive supply falls short of demand, Seagate (STX.US) and Western Digital (WDC.US) earnings reports may bring surprises
Wedbush reiterated its "outperform" ratings for Seagate and Western Digital, setting target prices at $1,000 and $650, respectively.

JPMorgan maintains Underweight rating on Nike (NKE.US): Deep in adjustment pains, performance pressures may persist until fiscal year 2028
Recently, JPMorgan released a U.S. equity research report on Nike. The research team participated in a face-to-face meeting with Nike's new CFO, Denton, updated profit assumptions based on management statements, and maintained an “underweight” investment rating on Nike.
